Table 1 Patient characteristics and associations with FYN expression in GC patients
From: FYN/TOPK/HSPB1 axis facilitates the proliferation and metastasis of gastric cancer
Characteristic | FYN high expression | FYN low expression | p |
|---|---|---|---|
n | 27 | 27 | Â |
status, n (%) | Â | Â | 0.352 |
 0 | 5 (9.3%) | 9 (16.7%) |  |
 1 | 22 (40.7%) | 18 (33.3%) |  |
gender, n (%) | Â | Â | 0.271 |
 female | 14 (25.9%) | 9 (16.7%) |  |
 male | 13 (24.1%) | 18 (33.3%) |  |
T stage, n (%) | Â | Â | 0.342 |
 T1b | 2 (3.7%) | 1 (1.9%) |  |
 T2 | 3 (5.6%) | 1 (1.9%) |  |
 T3 | 15 (27.8%) | 16 (29.6%) |  |
 T4a | 5 (9.3%) | 9 (16.7%) |  |
 T4b | 2 (3.7%) | 0 (0%) |  |
N stage, n (%) | Â | Â | 0.337 |
 N0 | 5 (9.3%) | 9 (16.7%) |  |
 N1 | 2 (3.7%) | 3 (5.6%) |  |
 N2 | 6 (11.1%) | 6 (11.1%) |  |
 N3a | 11 (20.4%) | 9 (16.7%) |  |
 N3b | 3 (5.6%) | 0 (0%) |  |
M stage, n (%) | Â | Â | 1.000 |
 M0 | 26 (48.1%) | 26 (48.1%) |  |
 M1 | 1 (1.9%) | 1 (1.9%) |  |
Clinical Stage, n (%) | Â | Â | 0.815 |
 1A | 1 (1.9%) | 1 (1.9%) |  |
 1B | 1 (1.9%) | 1 (1.9%) |  |
 2A | 4 (7.4%) | 7 (13%) |  |
 2B | 2 (3.7%) | 3 (5.6%) |  |
 3A | 5 (9.3%) | 1 (1.9%) |  |
 3B | 9 (16.7%) | 9 (16.7%) |  |
 3C | 4 (7.4%) | 4 (7.4%) |  |
 4 | 1 (1.9%) | 1 (1.9%) |  |
Pathologic stage, n (%) | Â | Â | 1.000 |
 II | 7 (13%) | 7 (13%) |  |
 II-III | 4 (7.4%) | 4 (7.4%) |  |
 III | 16 (29.6%) | 16 (29.6%) |  |
 H-score(FYN), meidan (IQR) | 108.5 (100.81, 125.34) | 62.25 (53.14, 72.79) |  < 0.001 |
 time, meidan (IQR) | 19 (11.5, 47.5) | 46 (20.5, 77) | 0.052 |
 age, mean ± SD | 56.93 ± 14.52 | 59.81 ± 8.88 | 0.383 |
 Number of lymph node—positive, meidan (IQR) | 8 (2, 13) | 3 (0, 7) | 0.038 |